ACADIA Pharmaceuticals Inc. (ACAD)

25.70
0.45 1.70
NASDAQ : Health Technology
Prev Close 26.15
Open 26.10
Day Low/High 25.54 / 26.10
52 Wk Low/High 12.77 / 28.67
Volume 1.14M
Avg Volume 1.00M
Exchange NASDAQ
Shares Outstanding 144.17M
Market Cap 3.69B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
ACADIA Pharmaceuticals Stock Trading Halted Today

ACADIA Pharmaceuticals Stock Trading Halted Today

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

7 Stocks Seeing Big Volume Today -- and How You Should Trade Them Now

7 Stocks Seeing Big Volume Today -- and How You Should Trade Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Acadia Pharmaceuticals (ACAD) Stock Soars Ahead of Tuesday Panel

Acadia Pharmaceuticals (ACAD) Stock Soars Ahead of Tuesday Panel

Acadia Pharmaceuticals (ACAD) stock is surging on Monday morning ahead of tomorrow’s meeting of experts chosen by the FDA to discuss the company’s Nuplazid drug.

ACADIA Pharmaceuticals (ACAD): Heavy Pre-Market Activity

ACADIA Pharmaceuticals (ACAD): Heavy Pre-Market Activity

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a pre-market mover with heavy volume candidate

U.S. Futures Have Strong Start to Week

U.S. futures are climbing Monday after major indices experienced a dip in trading last week.

Acadia's Parkinson's Drug Hit With Critical FDA Review Ahead of Tuesday Panel

Acadia's Parkinson's Drug Hit With Critical FDA Review Ahead of Tuesday Panel

The outcome of the panel vote is very important to Acadia. An affirmative decision would most likely compel the FDA to approve Nuplazid by its decision date of May 1.

Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data

Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data

TheStreet's senior columnist Adam Feuerstein answers reader questions about biotech stocks.

ACADIA Pharmaceuticals (ACAD) Highlighted As Today's Perilous Reversal Stock

ACADIA Pharmaceuticals (ACAD) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

There Are Reasons for Acadia Investors to Be Optimistic About Nuplazid and the Company

There Are Reasons for Acadia Investors to Be Optimistic About Nuplazid and the Company

The FDA advisory committee is meeting on March 29 to discuss the future of Nuplazid, a drug for the potential treatment of Parkinson Disease Psychosis. There's reason to be optimistic.

Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

Biotech Stock Mailbag: Acadia, Relypsa, Celator

Biotech Stock Mailbag: Acadia, Relypsa, Celator

TheStreet's biotech columnist Adam Feuerstein answers reader questions about biotech stock investing.

Small-Cap Friday: ACADIA Pharmaceuticals

Small-Cap Friday: ACADIA Pharmaceuticals

I like the biopharma's risk/reward on potential sales of Nuplazid.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's "Perilous Reversal" Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock

ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

ACADIA Pharmaceuticals To Present At The Cowen And Company 36th Annual Health Care Conference On March 8, 2016

ACADIA Pharmaceuticals To Present At The Cowen And Company 36th Annual Health Care Conference On March 8, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2015 Financial Results On February 29, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a weak on high relative volume candidate

ACADIA Pharmaceuticals To Present At The LEERINK Partners 5th Annual Global Healthcare Conference On February 10, 2016

ACADIA Pharmaceuticals To Present At The LEERINK Partners 5th Annual Global Healthcare Conference On February 10, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting To Review NUPLAZID™ (Pimavanserin) For The Treatment Of Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting To Review NUPLAZID™ (Pimavanserin) For The Treatment Of Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., As Senior Vice President, Clinical Development And Chief Medical Officer

ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., As Senior Vice President, Clinical Development And Chief Medical Officer

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Strong On High Volume: ACADIA Pharmaceuticals (ACAD)

Strong On High Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

Analysts' Actions -- Alaska Air, Avon, Bristol-Myers, Goldman Sachs and More

Analysts' Actions -- Alaska Air, Avon, Bristol-Myers, Goldman Sachs and More

Here are Friday's top research calls, including upgrades for Alaska Air, Avon and Bristol-Myers, and a downgrade for Goldman Sachs.

Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD)

Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

TheStreet Quant Rating: D (Sell)